![[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Necitumumab IgG1 MAb ADCC 1 3 PTEN AKT STAT PI3-K pY pY pY GRB2 SOS RAS RAF MEK MAPK Gene activation Cell-cycle progression Survival (↓ apoptosis) Angiogenesis Proliferation Metastasis Chemo- therapy Radiation EGFR pool ↑ DNA repair activity 2 Necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody, targets the Epidermal Growth Factor Receptor (EGFR) Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, Katz T, Youssoufian H, Zhu J, Rowinsky EK, Voest EE. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res. 2010 Mar 15;16(6):1915-23. Epub 2010 Mar 2.](https://image.slidesharecdn.com/necitumumabimc-11f8ott2010-101021173739-phpapp02/85/necitumumab-imc-11-f8-ottobre-2010-1-320.jpg)
![[object Object],[object Object],Rationale for necitumumab ( IMC-11F8 ) in NSCLC ,[object Object],Marie Prewett, Rajiv Bassi, Hagop Youssoufian, Eric K. Rowinsky, James R. Tonra. The fully human EGFR antibody IMC-11F8 significantly increases the antitumor effects of cisplatin+gemcitabine in human non-small cell lung cancer models. AACR 2009, Abstract #2774 Imclone Systems, Data on File Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009 May 2;373(9674):1525-31.](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (20)
Similaire à Necitumumab imc 11 f8 ottobre 2010
Similaire à Necitumumab imc 11 f8 ottobre 2010 (20)
Plus de coolesanum
Plus de coolesanum (12)
Dernier
Dernier (20)
Necitumumab imc 11 f8 ottobre 2010
- 4. INSPIRE: phase III, 1st-line NSCLC, non-squamous www.clinicaltrials.gov ; NCT00982111; accessed on August 28 th , 2010 Primary endpoint: Overall Survival
- 5. SQUIRE: phase III, 1st-line NSCLC , squamous www.clinicaltrials.gov ; NCT00981058; accessed on August 28 th , 2010 Primary endpoint: Overall Survival
Notes de l'éditeur
- Karen: Do we have a more appropriate published reference?